June 26, 2006 – Johnson & Johnson dominated the news, spending a colossal amount of money to buy the consumer division of Pfizer and making a small investment in Metabolex, a privately held biotech with two diabetes compounds; Vasogen reported Celacade missed its endpoint in heart failure patients; Anadys abruptly halted clinical trials of its hepatitis C therapy; Tibotech won accelerated approval for Prezista, an HIV drug; Schering ended a partnership with NexMed for an erectile dysfunction drug; Ligand earned a milestone from Wyeth in their osteoporosis partnership; Pozen and GlaxoSmithKline released positive data on their migraine therapy, Trexima; Roche and Trimeris touted good results for their HIV fusion inhibitor; ViaCell won approval to test a cryopreservation product for human oocytes; and deCode reported positive data from a Cephalon drug for asthma. The Centient Biotech 200™ rose 20 points to 3572.82, an increase of .57%. More details...
